{"id":42845,"date":"2015-10-20T00:00:00","date_gmt":"2015-10-19T22:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/operaciones-sector-biotecnologia-minoryx-suanfarma-ability-pharma-oryzon-genomics\/"},"modified":"2025-03-12T11:35:40","modified_gmt":"2025-03-12T10:35:40","slug":"operaciones-sector-biotecnologia-minoryx-suanfarma-ability-pharma-oryzon-genomics","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/operaciones-sector-biotecnologia-minoryx-suanfarma-ability-pharma-oryzon-genomics\/","title":{"rendered":"Biotech operations: Minoryx, Suanfarma, Ability Pharma and Oryzon Genomics"},"content":{"rendered":"
According to data provided by Ascri, in the first half of 2015, biotechnology, with 24 transactions, is the sector with the second highest number of transactions. In the last month, we have witnessed several operations for an amount equal to or greater than \u20ac10M.<\/span><\/address>\n

<\/p>\n

Minoryx receives a \u20ac19M round of funding<\/strong><\/span><\/p>\n

Ysios Capital <\/a>has led the \u20ac19M round that has received Minorix<\/a>,<\/span> a company specialising in the discovery and development of new drugs for rare or minority diseases. The round was also attended by \u00a0Caixa Capital Risc<\/span><\/span><\/a>,<\/span> the venture capital division of \"la Caixa\", and specialised international investors:\u00a0Kurma Partners<\/span><\/a>,\u00a0Roche Venture Fund<\/span>,Idinvest Partners\u00a0<\/span><\/a>and\u00a0Chiesi Ventures<\/span><\/a>, y \u00a0Health Equity<\/span><\/a>,<\/span> which, together with Caixa Capital Risc, was already a shareholder of the company.<\/span><\/p>\n

The support of these investors is of great value to the company as they are investors with complementary perspectives, international in scope and with extensive knowledge in orphan drugs, as well as corporate investors from big pharma.<\/span><\/p>\n

The funds raised will be used to complete the team, primarily in R&D, to advance the MIN-102 lead project to clinical validation and to further develop a portfolio of non-competitive drug chaperones identified through the company's innovative SEE-Tx platform.<\/span><\/p>\n

Prior to this major operation, Minoryx has been able to mobilise more than \u20ac4M, and has also received support from the programmes Incompact,<\/a><\/span> Challenges and Torres Quevedo <\/a><\/span>by the Ministry of Economy and Competitiveness, the participative loans of ENISA<\/a> and<\/span> Nuclis and Eurotransbio grants from ACC1\u00d3.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

ProaCapital enters in Suanfarma<\/strong><\/span><\/p>\n

ProaCapital <\/a><\/span>has made the first purchase of its second fund, for which it has raised \u20ac350m, by entering Suanfarma. \u00a0<\/span><\/p>\n

\u00a0ProA Capital's entry into the shareholding has been materialised through a capital increase 25m to support the company's growth.<\/span><\/p>\n

Suanfarma<\/a><\/span> specialises in the development, production and marketing of raw materials and finished products for the pharmaceutical, biotechnology, veterinary, nutritional and cosmetic sectors. With annual sales of more than \u20ac80M, the Spanish company, founded in 1993, obtains more than 50% of its sales in international markets and, in particular, more than $30M in the United States.<\/span><\/p>\n

Ability Pharma opens $10M round of funding<\/strong><\/span><\/p>\n

Ability Pharma<\/a><\/span>AB Biotics' spin-off is investigating an effective drug against neuroblastoma cancer, a rare disease that mainly affects children.<\/span><\/p>\n

To start the phase 2 clinical trial of the drug ABTL0812, the firm needs a financing round and is already in talks with several funds and family offices. The $10M round is expected to close in the first half of 2016.<\/span><\/p>\n

Oryzon Genomics plans to go public <\/strong><\/span><\/p>\n

Oryzon<\/a>,<\/span> which researches therapies for neurodegenerative diseases, plans to go public on the Madrid stock exchange before 2016, in order to strengthen its position and be able to enter the US market by 2017.<\/span><\/p>\n

 <\/p>\n

If you are looking for financing, please contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Fill in the contact form or call us on +34 946424142<\/span><\/p>\n

Other posts that may interest you<\/span><\/strong><\/p>\n

Spanish biotech companies internationalise: Artax Biopharma, PharmaMar and Mind The Byte<\/a><\/span><\/p>\n

Biotech investment news September 2015: CaixaIpulse, Sanifit and Centauri<\/a><\/span><\/p>\n

Investment for the biotech sector: Tigenix, Ekuore and Grants4Apps<\/a><\/span><\/p>\n

\u00a0<\/strong><\/span><\/p>","protected":false},"excerpt":{"rendered":"

According to data provided by Ascri, in the first half of 2015, biotechnology, with 24 transactions, is the sector with the second highest number of transactions. In the last month, we have witnessed several operations for an amount equal to or greater than \u20ac10M.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1751],"tags":[238,407,216],"sectores":[],"tipo-contenido":[2260],"class_list":["post-42845","post","type-post","status-publish","format-standard","hentry","category-adquisiciones-mas-relevantes","tag-biotecnologia","tag-financiacion-para-biotecnologia","tag-rondas-de-financiacion","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=42845"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42845\/revisions"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=42845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=42845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=42845"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=42845"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=42845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}